Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SNSS

Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis

Sunesis Pharmaceuticals logo

About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.38
$5.32
52-Week Range
N/A
Volume
1.20 million shs
Average Volume
4.33 million shs
Market Capitalization
$96.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SNSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNSS Stock News Headlines

Peter J Barris's Net Worth
AQSZF Aequus Pharmaceuticals Inc.
Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
4 Breakout Stocks to Watch Going Into Labor Day
4 Stocks Under $10 to Trade Now
See More Headlines

SNSS Stock Analysis - Frequently Asked Questions

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.01.

Shares of Sunesis Pharmaceuticals reverse split before market open on Thursday, September 3rd 2020.The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunesis Pharmaceuticals investors own include SELLAS Life Sciences Group (SLS), Novavax (NVAX), NVIDIA (NVDA), QUALCOMM (QCOM), OPKO Health (OPK), TherapeuticsMD (TXMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
11/15/2020
Today
7/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SNSS
CIK
1061027
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-179.05%
Return on Assets
-72.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.74
Quick Ratio
7.74

Sales & Book Value

Annual Sales
$2.07 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
18,093,000
Free Float
N/A
Market Cap
$96.26 million
Optionable
Optionable
Beta
2.27
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SNSS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners